Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
about
The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.Recent therapeutic advances in chronic lymphocytic leukemia.Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.Microenvironmental agonists generate phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCLSustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p
P2860
Q38719429-69F6B1C0-562A-4709-A1CF-5A76E906676BQ39432317-06D50C50-D9EA-4DB4-B11F-D261874D4BB8Q46318389-58043B28-4CE2-450B-82F5-2429D29FE646Q47424531-7FEA42C8-EE4D-43F8-A735-A08A78E46AB0Q50054062-53BA00B9-8935-46E4-A702-71C5DBEE808BQ50072188-68AAA00F-8D91-46BD-9865-B86E0394B09DQ50121608-9AD2C547-8878-455C-8C57-D0C42706F4AEQ52723842-869D2CA9-4F45-432B-9C93-E83A696D57D1Q56514276-5FFBCB98-A446-40FC-8630-FE2AB115F168Q58776981-1F1D78DC-FFEB-4EDF-B9D7-09508037B210Q58790214-CDEE73F3-8DE9-4BF4-A3E7-9437F517CC29
P2860
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Long-term outcomes for patient ...... mia who discontinue ibrutinib.
@en
type
label
Long-term outcomes for patient ...... mia who discontinue ibrutinib.
@en
prefLabel
Long-term outcomes for patient ...... mia who discontinue ibrutinib.
@en
P2093
P2860
P50
P356
P1433
P1476
Long-term outcomes for patient ...... mia who discontinue ibrutinib.
@en
P2093
Jan A Burger
Nitin Jain
Philip A Thompson
Preetesh Jain
P2860
P304
P356
10.1002/CNCR.30596
P407
P577
2017-02-07T00:00:00Z